Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

STOK

Stoke Therapeutics Inc

Jul 26 • 04:00PM ET

15.86

Dollar change +1.30
Percentage change 8.93	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Financials • Options Chain • Save to Portfolio • Create Alert

Held by: VTI IWM XBI VXF IWO DWAS PTH SCHA VTWO VHT

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-2.42	Insider Own	25.38%	Shs Outstand	45.92M	Perf Week	16.79%
Market Cap	826.62M	Forward P/E	-	EPS next Y	-2.55	Insider Trans	-22.57%	Shs Float	38.89M	Perf Month	22.76%
Income	-108.53M	PEG	-	EPS next Q	-0.55	Inst Own	79.29%	Short Float	26.48%	Perf Quarter	35.67%
Sales	7.84M	P/S	105.44	EPS this Y	4.36%	Inst Trans	-1.58%	Short Ratio	13.33	Perf Half Y	227.69%
Book/sh	3.02	P/B	5.25	EPS next Y	-11.83%	ROA	-44.57%	Short Interest	10.30M	Perf Year	164.33%
Cash/sh	3.43	P/C	4.63	EPS next 5Y	-	ROE	-61.29%	52W Range	3.35 - 17.58	Perf YTD	201.52%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-44.06%	ROI	-75.12%	52W High	-9.78%	Beta	0.85
Dividend TTM	-	Quick Ratio	5.42	Sales past 5Y	-5.84%	Gross Margin	40.15%	52W Low	373.43%	ATR (14)	0.97
Dividend Ex-Date	-	Current Ratio	5.42	EPS Y/Y TTM	2.14%	Oper. Margin	-1509.93%	RSI (14)	61.41	Volatility	7.92% 6.52%
Employees	110	Debt/Eq	0.05	Sales Y/Y TTM	-46.11%	Profit Margin	-1383.40%	Recom	1.22	Target Price	22.14
Option/Short	Yes / Yes	LT Debt/Eq	0.03	EPS Q/Q	-7.60%	Payout	-	Rel Volume	1.22	Prev Close	14.56
Sales Surprise	29.31%	EPS Surprise	6.54%	Sales Q/Q	-18.17%	Earnings	May 06 BMO	Avg Volume	772.56K	Price	15.86
SMA20	14.95%	SMA50	9.56%	SMA200	84.41%	Trades		Volume	942,622	Change	8.93%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-26-24	Upgrade	TD Cowen	Market Perform → Outperform
Nov-20-23	Resumed	JP Morgan	Neutral
Jul-25-23	Downgrade	TD Cowen	Outperform → Market Perform
May-01-23	Upgrade	BofA Securities	Underperform → Neutral	$9 → $12
Apr-26-23	Resumed	Canaccord Genuity	Buy	$24
Jan-06-23	Downgrade	BofA Securities	Buy → Underperform	$22 → $9
Oct-24-22	Upgrade	SVB Leerink	Mkt Perform → Outperform	$30
Jan-31-22	Initiated	Jefferies	Buy	$50
Dec-03-21	Initiated	BofA Securities	Buy	$43
Nov-22-21	Upgrade	JP Morgan	Neutral → Overweight	$41
May-18-21	Initiated	UBS	Neutral	$35
May-10-21	Upgrade	Wedbush	Neutral → Outperform
Apr-26-21	Resumed	Credit Suisse	Outperform	$58
Feb-10-21	Downgrade	Wedbush	Outperform → Neutral
Dec-15-20	Resumed	H.C. Wainwright	Buy	$70
Dec-11-20	Reiterated	Needham	Buy	$48 → $56
Oct-23-20	Initiated	Cantor Fitzgerald	Overweight	$49
Sep-29-20	Resumed	JP Morgan	Neutral	$34
Sep-29-20	Initiated	Needham	Buy	$42
Dec-18-19	Initiated	Wedbush	Outperform	$31

Show Previous Ratings

Jul-16-24 04:30PM	Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) (Business Wire) -7.19%
Jun-18-24 04:30PM	Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) (Business Wire)
Jun-13-24 09:00AM	The Lustgarten Foundation Appoints Two New Board Members (PR Newswire)
Jun-03-24 04:30PM	Stoke Therapeutics to Present at Upcoming Investor Conferences in June (Business Wire) +5.88%
May-22-24 07:07PM	Insider Sale: CEO Edward M. Kaye of Stoke Therapeutics Inc (STOK) Sells 42,350 Shares (GuruFocus.com) -6.96%
04:30PM	Loading…
May-17-24 04:30PM	Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) (Business Wire) +15.83%
May-07-24 09:04PM	Stoke Therapeutics Inc (STOK) Reports Q1 2024 Financial Results: A Closer Look at Challenges ... (GuruFocus.com)
10:30AM	Canaccord Genuity Adjusts Price Target on Stoke Therapeutics to $20 From $21, Maintains Buy Rating (MT Newswires)
May-06-24 11:53AM	STOK Stock Earnings: Stoke Therapeutics Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace)
08:05AM	Stoke Therapeutics, Inc. (STOK) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
07:00AM	Stoke Therapeutics Reports First Quarter Financial Results and Provides Business Updates (Business Wire)
Apr-29-24 10:21AM	Stoke Therapeutics Appoints Thomas Leggett CFO (MT Newswires)
08:00AM	Stoke Therapeutics Appoints Thomas Leggett as Chief Financial Officer (Business Wire)
Apr-25-24 10:01AM	Earnings Preview: Stoke Therapeutics, Inc. (STOK) Q1 Earnings Expected to Decline (Zacks)
Apr-23-24 07:45AM	Garry Menzel joins GHO Capital as Operating Partner (GlobeNewswire)
08:00AM	Loading…
Apr-17-24 08:00AM	Stoke Therapeutics Appoints Jason Hoitt as Chief Commercial Officer (Business Wire) -5.86%
Apr-04-24 04:30PM	Stoke Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference (Business Wire) -5.03%
Mar-27-24 11:40PM	Stoke Therapeutics Announces Pricing of Upsized $125 Million Public Offering (Business Wire) +37.71%
08:50AM	Stoke Therapeutics (STOK) Up on Upbeat Dravet Syndrome Study Data (Zacks)
Mar-26-24 04:07PM	Stoke Therapeutics Announces Proposed Public Offering (Business Wire) +58.31%
11:20AM	Stoke Therapeutics' Anti-Epilepsy Drug Candidate Shows Substantial, Sustained Reductions In Seizure Frequency In Pretreated Patients (Benzinga)
07:54AM	Why Is Stoke Therapeutics (STOK) Stock Up 99% Today? (InvestorPlace)
07:49AM	Stoke shares surge on updated results for Dravet drug (BioPharma Dive)
Mar-25-24 09:53PM	STOK Stock Earnings: Stoke Therapeutics Beats EPS, Misses Revenue for Q4 2023 (InvestorPlace)
05:10PM	Stoke Therapeutics, Inc. (STOK) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
04:01PM	Stoke Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results (Business Wire)
04:01PM	Stoke Therapeutics Announces Landmark New Data That Support the Potential for STK-001 to be the First Disease-Modifying Medicine for the Treatment of Patients with Dravet Syndrome (Business Wire)
Feb-29-24 08:50AM	Why Earnings Season Could Be Great for Stoke Therapeutics (STOK) (Zacks)
Feb-26-24 10:00AM	Stoke Therapeutics, Inc. (STOK) Expected to Beat Earnings Estimates: Should You Buy? (Zacks) +11.95%
Feb-25-24 01:37PM	7 Biotech Penny Stocks on the Verge of Clinical Trial Victory (InvestorPlace)
02:31PM	Loading…
Feb-19-24 02:31PM	Triple Threat: 3 Stocks to Buy for 3X Upside Potential (InvestorPlace)
Feb-15-24 09:55AM	Does Stoke Therapeutics, Inc. (STOK) Have the Potential to Rally 284.14% as Wall Street Analysts Expect? (Zacks)
06:59AM	Stoke Therapeutics, Inc. (STOK) Stock Jumps 25.5%: Will It Continue to Soar? (Zacks)
Jan-17-24 04:30PM	Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) (Business Wire)
Jan-08-24 08:00AM	Stoke Therapeutics Highlights Strategic Priorities and Anticipated Milestones for 2024 (Business Wire)
Jan-04-24 04:30PM	Stoke Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference (Business Wire)
Jan-02-24 10:29AM	Why healthcare, biotech may be top plays for 2024: BTIG (Yahoo Finance Video) +11.41%
Dec-14-23 09:55AM	Wall Street Analysts Predict a 220.81% Upside in Stoke Therapeutics, Inc. (STOK): Here's What You Should Know (Zacks)
Dec-01-23 09:00AM	Stoke Therapeutics Presents Data From Multiple Studies of Children and Adolescents With Dravet Syndrome at the American Epilepsy Society (AES) 2023 Annual Meeting (Business Wire)
Nov-21-23 08:00AM	Stoke Therapeutics to Present Data from the Companys Dravet Syndrome Clinical Program at the American Epilepsy Society 2023 Annual Meeting (Business Wire) -6.47%
Nov-09-23 05:48AM	Stoke Therapeutics Inc (STOK) Reports Q3 Financial Results and Progress in Dravet Syndrome Treatment (GuruFocus.com)
Nov-07-23 07:00AM	Stoke Therapeutics Reports Third Quarter Financial Results and Provides Business Updates (Business Wire) +12.53%
Oct-17-23 04:30PM	Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) (Business Wire) -6.80%
Sep-21-23 08:00AM	Stoke Therapeutics to Participate in the 2023 Cantor Global Healthcare Conference (Business Wire) -6.53%
Sep-20-23 04:30PM	Stoke Therapeutics Appoints Ian Smith to its Board of Directors (Business Wire) -6.72%
Sep-05-23 07:00AM	Stoke Therapeutics Presents Data Related to the Ongoing Clinical Development of STK-001 for the Treatment of Dravet Syndrome at the 35th International Epilepsy Congress (Business Wire)
Aug-16-23 01:00PM	This Under-the-Radar Growth Stock Could Soar by 277%, According to Wall Street (Motley Fool)
Aug-08-23 06:02AM	Stoke Therapeutics Second Quarter 2023 Earnings: Misses Expectations (Simply Wall St.) -5.13%
Aug-07-23 08:15AM	Stoke Therapeutics, Inc. (STOK) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
07:00AM	Stoke Therapeutics Reports Second Quarter Financial Results and Provides Business Updates (Business Wire)
Aug-02-23 08:00AM	Stoke Therapeutics to Present at the Canaccord Genuity 43rd Annual Growth Conference (Business Wire)
Jul-25-23 02:32PM	Why Shares of Stoke Therapeutics Plummeted Tuesday (Motley Fool) -32.11%
07:00AM	Stoke Therapeutics Announces Positive New Safety & Efficacy Data from Patients Treated with STK-001 in the Phase 1/2a Studies (MONARCH & ADMIRAL) and the SWALLOWTAIL Open-Label Extension (OLE) Study in Children and Adolescents with Dravet Syndrome (Business Wire)
Jul-21-23 07:30AM	Stoke Therapeutics to Host Webinar to Present New Data from Patients Treated with STK-001 in the Phase 1/2a Studies (MONARCH & ADMIRAL) and the SWALLOWTAIL Open-Label Extension (OLE) Study in Children and Adolescents with Dravet Syndrome (Business Wire) +7.73%
Jul-05-23 01:20PM	Here's Why We're Not Too Worried About Stoke Therapeutics' (NASDAQ:STOK) Cash Burn Situation (Simply Wall St.)
Jun-21-23 04:22AM	Stoke Therapeutics, Inc. (STOK) Surges 6.3%: Is This an Indication of Further Gains? (Zacks)
Jun-16-23 04:30PM	Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) (Business Wire) +6.31%
Jun-14-23 09:55AM	Should You Buy Stoke Therapeutics, Inc. (STOK) After Golden Cross? (Zacks)
May-09-23 09:55AM	How Much Upside is Left in Stoke Therapeutics, Inc. (STOK)? Wall Street Analysts Think 102.91% (Zacks)
06:04AM	New Forecasts: Here's What Analysts Think The Future Holds For Stoke Therapeutics, Inc. (NASDAQ:STOK) (Simply Wall St.)
May-06-23 08:03AM	Earnings Update: Stoke Therapeutics, Inc. (NASDAQ:STOK) Just Reported And Analysts Are Boosting Their Estimates (Simply Wall St.)
May-04-23 10:00AM	Analysts Estimate Synlogic, Inc. (SYBX) to Report a Decline in Earnings: What to Look Out for (Zacks) +12.96%
08:55AM	Stoke Therapeutics, Inc. (STOK) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
07:00AM	Stoke Therapeutics Reports First Quarter Financial Results and Provides Business Updates (Business Wire)
May-03-23 08:00AM	Stoke Therapeutics to Present at the BofA Securities Health Care Conference (Business Wire)
May-02-23 10:02AM	Stoke Therapeutics, Inc. (STOK) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
Apr-25-23 07:00AM	Stoke Therapeutics Receives Authorization to Initiate a Phase 1/2 Study of STK-002 for Autosomal Dominant Optic Atrophy (ADOA) in the United Kingdom (Business Wire)
Mar-28-23 10:40AM	Investors in Stoke Therapeutics (NASDAQ:STOK) have unfortunately lost 64% over the last three years (Simply Wall St.)
Mar-15-23 07:00AM	Stoke Therapeutics Announces That FDA Will Allow the Administration of a Higher Single Dose of STK-001 (70mg) in the Ongoing Phase 1/2a MONARCH Study of Children and Adolescents with Dravet Syndrome (Business Wire) -6.92%
Mar-06-23 08:15AM	Stoke Therapeutics, Inc. (STOK) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
07:00AM	Stoke Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Updates (Business Wire)
Feb-27-23 04:30PM	Stoke Therapeutics to Participate at Upcoming March Investor Conferences (Business Wire)
Feb-07-23 08:00AM	Stoke Therapeutics to Present at the SVB Securities Global Biopharma Conference (Business Wire)
Jan-26-23 05:59AM	Companies Like Stoke Therapeutics (NASDAQ:STOK) Can Afford To Invest In Growth (Simply Wall St.)
Jan-09-23 08:00AM	Stoke Therapeutics Highlights Strategic Priorities and Anticipated Milestones for 2023 (Business Wire)
Jan-04-23 08:00AM	Stoke Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference (Business Wire) +6.16%
Dec-02-22 09:00AM	Stoke Therapeutics Presents Data from a Combined Interim Analysis of the Phase 1/2a MONARCH and ADMIRAL Studies of STK-001 in Children and Adolescents with Dravet Syndrome at the American Epilepsy Society (AES) 2022 Annual Meeting (Business Wire)
Nov-29-22 07:30AM	Stoke Therapeutics to Present Data from the Companys Dravet Syndrome Program at the American Epilepsy Society 2022 Annual Meeting (Business Wire)
Nov-14-22 01:02PM	Stoke Therapeutics Stock Falls Post Early Efficacy Data From Lead Dravet Syndrome Program (Benzinga) -25.30%
08:25AM	Stoke Therapeutics, Inc. (STOK) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
07:00AM	Stoke Therapeutics Reports Third Quarter Financial Results and Provides Business Updates (Business Wire)
Nov-10-22 08:32AM	Is a Surprise Coming for Stoke Therapeutics (STOK) This Earnings Season? (Zacks)
07:30AM	Stoke Therapeutics to Host Webinar and Conference Call to Present Interim Data from the Phase 1/2a Studies of STK-001 in Children and Adolescents with Dravet Syndrome (Business Wire)
Nov-07-22 09:55AM	Stoke Therapeutics, Inc. (STOK) Forms 'Hammer Chart Pattern': Time for Bottom Fishing? (Zacks)
Oct-19-22 10:02AM	Stoke Therapeutics (NASDAQ:STOK) adds US$56m to market cap in the past 7 days, though investors from a year ago are still down 43% (Simply Wall St.)
Aug-25-22 07:30AM	Stoke Therapeutics Enrolls First Patient in a Natural History Study of People Living with Autosomal Dominant Optic Atrophy (ADOA) (Business Wire)
Aug-19-22 06:40AM	We're Interested To See How Stoke Therapeutics (NASDAQ:STOK) Uses Its Cash Hoard To Grow (Simply Wall St.)
Aug-10-22 09:55AM	How Much Upside is Left in Stoke Therapeutics, Inc. (STOK)? Wall Street Analysts Think 91% (Zacks)
Aug-09-22 11:54AM	7 Stocks Due for a Stunning Short Squeeze (InvestorPlace)
Aug-08-22 08:15AM	Stoke Therapeutics, Inc. (STOK) Reports Q2 Loss, Tops Revenue Estimates (Zacks) +26.03%
07:00AM	Stoke Therapeutics Reports Second Quarter Financial Results and Provides Business Updates (Business Wire)
Jun-01-22 02:00PM	Scientist needed to come out as gay before founding a biotech (American City Business Journals)
07:30AM	Stoke Therapeutics to Present at the 2022 Jefferies Healthcare Conference (Business Wire)
May-12-22 07:44AM	Stoke Therapeutics (NASDAQ:STOK shareholders incur further losses as stock declines 15% this week, taking one-year losses to 64% (Simply Wall St.) +5.95%
May-10-22 07:00AM	Stoke Therapeutics Reports First Quarter Financial Results and Provides Business Updates (Business Wire) +7.96%
May-05-22 10:06AM	Acadia (ACAD) Q1 Earnings & Revenues Fall Shy of Estimates (Zacks) -7.32%
May-02-22 04:35PM	Stoke Therapeutics Presents New In-Vivo Data That Demonstrated Dose-Related Target Engagement and OPA1 Protein Upregulation in Retinal Tissue Following Administration of STK-002 (Business Wire)
Apr-07-22 07:30AM	Stoke Therapeutics to Present at The Association for Research in Vision and Ophthalmology (ARVO) 2022 Annual Meeting (Business Wire)
Apr-05-22 07:30AM	Stoke Therapeutics to Present at the 21st Annual Needham Virtual Healthcare Conference (Business Wire)
Mar-10-22 07:00AM	Stoke Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Updates (Business Wire)

Stoke Therapeutics, Inc. is a biotechnology company, which engages in the research and development of treatments for genetic diseases. It offers a wide range of relevant tissues including the central nervous system, eye, kidney, and liver. The company was founded by Isabel Aznarez and Adrian R. Krainer in June 2014 and is headquartered in Bedford, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Nash Huw M.	Chief Business Officer	Jul 02 '24	Sale	13.11	2,500	32,779	0	Jul 03 04:13 PM
Ticho Barry	CHIEF MEDICAL OFFICER	Jul 01 '24	Option Exercise	0.60	10,000	6,000	12,485	Jul 03 04:11 PM
Ticho Barry	CHIEF MEDICAL OFFICER	Jul 01 '24	Sale	13.75	10,000	137,458	2,485	Jul 03 04:11 PM
Ticho Barry	CHIEF MEDICAL OFFICER	Jun 03 '24	Option Exercise	0.60	10,000	6,000	12,485	Jun 05 04:18 PM
Ticho Barry	CHIEF MEDICAL OFFICER	Jun 03 '24	Sale	15.22	10,000	152,185	2,485	Jun 05 04:18 PM
Allan Jonathan	GENERAL COUNSEL & CORP SEC	May 20 '24	Option Exercise	7.07	8,599	60,795	11,197	May 22 04:15 PM
Nash Huw M.	COO & CBO	May 20 '24	Option Exercise	0.40	50,000	20,000	50,000	May 22 04:20 PM
Nash Huw M.	COO & CBO	May 20 '24	Sale	15.39	50,000	769,500	0	May 22 04:20 PM
Kaye Edward M. MD	CEO	May 20 '24	Sale	15.43	42,350	653,529	27,000	May 22 04:17 PM
Allan Jonathan	GENERAL COUNSEL & CORP SEC	May 20 '24	Sale	15.04	8,599	129,327	2,598	May 22 04:15 PM
Ticho Barry	CHIEF MEDICAL OFFICER	May 01 '24	Option Exercise	0.60	10,000	6,000	12,485	May 03 04:24 PM
Ticho Barry	CHIEF MEDICAL OFFICER	May 01 '24	Sale	11.37	10,000	113,653	2,485	May 03 04:24 PM
Skorpios Trust	10% Owner	Apr 17 '24	Sale	11.60	3,600,000	41,760,000	10,843,681	Apr 18 04:16 PM
Nash Huw M.	COO & CBO	Apr 01 '24	Option Exercise	0.40	50,000	20,000	61,329	Apr 03 04:19 PM
Ticho Barry	CHIEF MEDICAL OFFICER	Apr 01 '24	Option Exercise	0.60	442	265	11,911	Apr 03 04:21 PM
Nash Huw M.	COO & CBO	Apr 01 '24	Sale	13.23	61,329	811,212	0	Apr 03 04:19 PM
Ticho Barry	CHIEF MEDICAL OFFICER	Apr 01 '24	Sale	13.23	9,426	124,684	2,485	Apr 03 04:21 PM
Allan Jonathan	GENERAL COUNSEL & CORP SEC	Mar 28 '24	Sale	13.20	5,126	67,668	2,598	Apr 01 04:14 PM
Kaye Edward M. MD	CEO	Mar 19 '24	Sale	6.10	11,150	67,999	69,350	Mar 19 08:30 PM
Nash Huw M.	COO & CBO	Mar 19 '24	Sale	6.10	4,116	25,102	11,329	Mar 19 08:31 PM
Ticho Barry	CHIEF MEDICAL OFFICER	Mar 19 '24	Sale	6.10	4,116	25,102	11,469	Mar 19 08:34 PM
Tulipano Stephen J	CFO	Mar 19 '24	Sale	6.10	4,116	25,102	20,746	Mar 19 08:36 PM
Allan Jonathan	GENERAL COUNSEL & CORP SEC	Mar 19 '24	Sale	6.10	2,349	14,326	7,724	Mar 19 08:29 PM
Tulipano Stephen J	CFO	Mar 15 '24	Option Exercise	0.00	13,100	0	24,862	Mar 19 08:36 PM
Ticho Barry	CHIEF MEDICAL OFFICER	Mar 15 '24	Option Exercise	0.00	13,100	0	15,585	Mar 19 08:34 PM
Nash Huw M.	COO & CBO	Mar 15 '24	Option Exercise	0.00	13,100	0	15,445	Mar 19 08:31 PM
Kaye Edward M. MD	CEO	Mar 15 '24	Option Exercise	0.00	35,500	0	80,500	Mar 19 08:30 PM
Allan Jonathan	GENERAL COUNSEL & CORP SEC	Mar 15 '24	Option Exercise	0.00	7,475	0	10,073	Mar 19 08:29 PM
Ticho Barry	CHIEF MEDICAL OFFICER	Mar 01 '24	Option Exercise	0.60	5,504	3,302	12,485	Mar 05 04:21 PM
Ticho Barry	CHIEF MEDICAL OFFICER	Mar 01 '24	Sale	7.75	10,000	77,469	2,485	Mar 05 04:21 PM
TZIANABOS ARTHUR	Director	Feb 13 '24	Option Exercise	2.19	31,739	69,508	31,739	Feb 15 04:17 PM
Ticho Barry	CHIEF MEDICAL OFFICER	Feb 01 '24	Sale	4.80	10,000	47,991	6,981	Feb 05 04:32 PM
Ticho Barry	Chief Medical Officer	Jan 02 '24	Sale	5.74	10,000	57,352	16,981	Jan 04 04:38 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

STOK

Stoke Therapeutics Inc

Upgrade your FINVIZ experience